US 12,077,581 B2
Anti-PACAP antibodies and uses thereof
Maria-Cristina Loomis, Bothell, WA (US); Leon F. Garcia-Martinez, Woodinville, WA (US); Benjamin H. Dutzar, Seattle, WA (US); Daniel S. Allison, Lake Forest Park, WA (US); Katherine Lee Hendrix, Renton, WA (US); Ethan W. Ojala, Snohomish, WA (US); Pei Fan, Bothell, WA (US); Jeffrey T. L. Smith, Bellevue, WA (US); John A. Latham, Seattle, WA (US); Charlie Karasek, Seattle, WA (US); Jenny Mulligan, Lake Forest Park, WA (US); Michelle Scalley-Kim, Seattle, WA (US); Erica Stewart, Seattle, WA (US); Vanessa Lisbeth Rubin, Seattle, WA (US); and Jens J. Billgren, Bothell, WA (US)
Assigned to H. LUNDBECK A/S, Valby (DK)
Filed by H. LUNDBECK A/S, Valby (DK)
Filed on Dec. 16, 2021, as Appl. No. 17/553,280.
Application 17/553,280 is a division of application No. 16/242,792, filed on Jan. 8, 2019, granted, now 11,254,741.
Application 16/242,792 is a division of application No. 15/130,263, filed on Apr. 15, 2016, abandoned.
Claims priority of provisional application 62/148,583, filed on Apr. 16, 2015.
Claims priority of provisional application 62/148,557, filed on Apr. 16, 2015.
Claims priority of provisional application 62/148,550, filed on Apr. 16, 2015.
Claims priority of provisional application 62/148,562, filed on Apr. 16, 2015.
Claims priority of provisional application 62/148,643, filed on Apr. 16, 2015.
Claims priority of provisional application 62/148,640, filed on Apr. 16, 2015.
Claims priority of provisional application 62/148,596, filed on Apr. 16, 2015.
Prior Publication US 2022/0289836 A1, Sep. 15, 2022
Int. Cl. C07K 16/26 (2006.01); A61K 39/395 (2006.01); A61P 25/06 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61K 49/00 (2006.01); C07K 14/575 (2006.01); C07K 16/42 (2006.01); G01N 33/50 (2006.01); G01N 33/74 (2006.01)
CPC C07K 16/26 (2013.01) [A61K 39/3955 (2013.01); A61P 25/06 (2018.01); A61K 39/39566 (2013.01); A61K 2039/505 (2013.01); A61K 45/06 (2013.01); A61K 49/0004 (2013.01); A61K 49/0008 (2013.01); C07K 14/57536 (2013.01); C07K 14/57563 (2013.01); C07K 16/4241 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/40 (2013.01); C07K 2317/50 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 33/5088 (2013.01); G01N 33/74 (2013.01); G01N 2333/5757 (2013.01); Y02A 50/30 (2018.01)] 18 Claims
 
1. A nucleic acid or nucleic acids which encode for an anti-human Pituitary Adenylate Cyclase-Activating Polypeptide (“PACAP”) antibody or antigen-binding fragment thereof that antagonizes, inhibits, neutralizes or blocks at least one biological effect associated with human PACAP, wherein said anti-human PACAP antibody or antigen-binding fragment thereof comprises:
(A)
(i) a variable heavy chain polypeptide comprising complementarity determining region 1, 2 and 3 (CDR1, CDR2 and CDR3) polypeptides respectively comprising the amino acid sequences of SEQ ID NO: 604; SEQ ID NO: 606; and SEQ ID NO: 608; and
(ii) a variable light chain polypeptide comprising CDR1, CDR2 and CDR3 polypeptides respectively comprising the amino acid sequences of SEQ ID NO: 624; SEQ ID NO: 626; and SEQ ID NO: 628; or
(B)
(i) a variable heavy chain polypeptide comprising CDR1, CDR2 and CDR3 polypeptides respectively comprising the amino acid sequences of SEQ ID NO: 564; and SEQ ID NO: 566; and SEQ ID NO: 568, and
(ii) a variable light chain polypeptide comprising CDR1, CDR2 and CDR3 polypeptides respectively comprising the amino acid sequences of SEQ ID NO: 584; SEQ ID NO: 586; and SEQ ID NO: 588.